Jason Harris

January 24, 2023

The median overall survival with nivolumab plus chemotherapy was 12.8 months, vs 10.7 months with chemotherapy alone, in patients with treatment-naïve advanced esophageal squamous cell carcinoma.

January 14, 2023

Findings showed that Black patients were 4.3 percentage points less likely to receive any opioid and 3.1 percentage points less likely to receive long-acting opioids near end-of-life compared with White patients.

January 04, 2023

Glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, elicited encouraging response rates in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 1/2 study.

December 03, 2022

Combining enzalutamide with salvage radiation therapy helped delay prostate-specific antigen progression in patients with PSA-recurrent, high-risk prostate cancer.

November 23, 2022

The autologous tumor lysate-loaded dendritic cell vaccination reduced the risk of death for patients with newly diagnosed glioblastoma by 20%.

November 19, 2022

As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.

November 06, 2022

At a 5-year follow-up, the failure-free survival rate with capecitabine was 83.3% vs 72.2% with observation.

October 22, 2022

Patients with heavily pretreated clear cell gynecologic cancer achieved encouraging responses with single-agent pembrolizumab.

October 21, 2022

The overall survival benefit associated with pembrolizumab for patients with head and neck cancer continued to be observed at a 4-year follow-up of the KEYNOTE-048 trial.

October 02, 2022

Following potential safety concerns with 3 PARP inhibitors, manufactures have voluntarily elected to withdraw the indications for patients with heavily pretreated patients with BRCA-mutated ovarian cancer.